OCGN Jan 2023 2.500 call
| Previous close | 0.9000 |
| Open | 0.9000 |
| Bid | 0.8000 |
| Ask | 1.1900 |
| Strike | 2.50 |
| Expiry date | 2023-01-20 |
| Day's range | 0.9000 - 0.9300 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.4k |
- Motley Fool
1 Robinhood Stock to Avoid Right Now
Commission-free trading platform Robinhood Markets grew in prominence helping newer investors participate in what remains one of the best ways to accumulate wealth over time. One example is Ocugen (NASDAQ: OCGN). Can Ocugen succeed in the COVID-19 vaccine market?
- GlobeNewswire
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17. A video webcast of the presentation will be availabl
- Motley Fool
Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript
Joining me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more on our financial results. Earlier this morning, we issued a press release detailing business activity for Q2 2022.
